International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 3 , Pages 548-557 , 1 July 2002

Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04 1

  • R Komaki, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Ritsuko Komaki, M.D., Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 97, Houston, TX 77030. USA Tel: 713-792-3420; Fax: 713-745-5573
    • The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • W Seiferheld, M.S.

      Affiliations

    • Radiation Therapy Oncology Group Headquarters, Philadelphia, PA, USA
    • ,
  • D Ettinger, M.D.

      Affiliations

    • Johns Hopkins Hospitals, Baltimore, MD, USA
    • ,
  • J.S Lee, M.D.

      Affiliations

    • The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • B Movsas, M.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • W Sause, M.D.

      Affiliations

    • Latter Day Saints Hospital, Salt Lake City, UT, USA

Received 1 November 2001 ,Revised 1 February 2002 ,Accepted 6 February 2002.

References 

  1. Kubota K, Furuse K, Kawahara M, et al.  Role of radiotherapy in combined modality treatment of locally advanced nonsmall cell lung cancer. J Clin Oncol. 1994;12:1547–1552
  2. Dillman RO, Herndon J, Seagren SL, et al.  Improved survival in stage III non-small cell lung cancer (Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial). J Natl Cancer Inst. 1996;88:1210–1216
  3. Sause WT, Scott C, Taylor S, et al.  Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588 (Preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer). J Natl Cancer Inst. 1995;87:198–205
  4. Saunders MI, Bennett MH, Dische S, et al.  Primary tumor control after radiotherapy for carcinoma of the bronchus. Int J Radiat Oncol Biol Phys. 1984;10:499–501
  5. Arriagada R, Le Chevalier T, Quoix E, et al.  Effect of chemotherapy on locally advanced nonsmall cell lung carcinoma (A randomized study of 353 patients—GETCB, FNCLCC, and the CEBI trialists). Int J Radiat Oncol Biol Phys. 1991;20:1183–1190
  6. Schaake-Koning C, van den Bogaert W, Dalesio O, et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524–530
  7. Lee JS, Scott C, Komaki R, et al.  Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable nonsmall cell lung cancer (Radiation Therapy Oncology Group Protocol 91-06). J Clin Oncol. 1996;14:1055–1064
  8. Sause WT, Scott C, Taylor S, et al.  Phase II trial of combination chemotherapy and irradiation in nonsmall cell lung cancer (Radiation Therapy Oncology Group 88-04). Am J Clin Oncol. 1992;15:163–167
  9. American Joint Committee on Cancer . In: AJCC cancer staging manual. 5th ed.. Philadelphia: Lippincott-Raven; 1997;p. 127–137
  10. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  11. Diener-West M, Pajak TF, Bauer M, et al.  Randomized dose searching phase I LE/II trials of fractionation in radiation therapy for cancer. J Natl Cancer Inst. 1991;83:1065–1071
  12. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143–151
  13. Perez CA, Pajak TF, Rubin P, et al.  Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy (Report by the Radiation Oncology Group). Cancer. 1987;59:1874–1881
  14. In: StatXact user manual. Cambridge: Cytel Software; 1992;p. 5.21–5.26
  15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  16. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;334:187–220
  17. Peto R, Pike MC, Armitage P, et al.  Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer. 1977;35:1–39
  18. Le Chevalier T, Arriagada R, Quoix E, et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable nonsmall cell lung cancer (First analysis of a randomized trial in 353 patients). J Natl Cancer Inst. 1991;83:417–423
  19. Le Chevalier T, Arriagada R, Quoix E, et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable nonsmall cell lung carcinoma. Lung Cancer. 1994;10(Suppl. 1):S239–S244
  20. Reboul F, Brewer Y, Vincent P, et al.  Concurrent chemoradiation for stage III nonsmall cell lung cancer (From cisplatin alone to cisplatin + etoposide). [Abstract] Lung Cancer. 1994;11(Suppl. 1):177
  21. Curran WJ, Scott C, Langer R, et al.  Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC) (initial report of Radiation Therapy Oncology Group (RTOG) 9410). [Abstract] J Clin Oncol. 2000;19:484
  22. Komaki R, Seiferheld W, Curran W, et al.  Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC) (Analysis of failures in a phase III study (RTOG 9410)). [Abstract] Int J Radiat Oncol Biol Phys. 2000;48:113
  23. Furuse K, Fukuoka M, Kawahara M, et al.  Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  24. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  25. Komaki R, Lee JS, Kaplan B, et al.  Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer (Preliminary results). Sem Radiat Oncol. 2002;12(Suppl. 1):46–69
  26. Fossella FV, Zinner RG, Komaki R, et al.  Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP) (A phase I trial for patients with stage III non-small cell lung cancer (NSCLC)). [Abstract] J Clin Oncol. 2001;20:312a

☆ Supported by Grant RTOG U10 CA21661, CCOP U10 CA37422, Stat U10 CA32115 from the National Cancer Institute.

PII: S0360-3016(02)02793-1

International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 3 , Pages 548-557 , 1 July 2002

Article Tools

* Image Usage & Resolution